NeuroSense Therapeutics (NRSN) Other Accumulated Expenses (2021 - 2025)

NeuroSense Therapeutics has reported Other Accumulated Expenses for 5 years, with the latest figure at $1.7 million in Q4 2025.

• Quarterly Other Accumulated Expenses rose 106.37% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (up 106.37% YoY) and the FY2025 annual result came in at $1.7 million, up 106.37% from the prior year.
• Other Accumulated Expenses climbed to $1.7 million in Q4 2025 per NRSN's latest filing, from $1.1 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.9 billion in Q2 2023 and troughed at $558000.0 in Q4 2021.
• A 5-year average of $129.0 million and a median of $1.4 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses surged 310776.62% in 2023, then tumbled 99.89% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $558000.0 in 2021, then soared by 120.07% to $1.2 million in 2022, then jumped by 62.87% to $2.0 million in 2023, then slumped by 58.4% to $832000.0 in 2024, then jumped by 106.37% to $1.7 million in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.7 million, $1.1 million, and $832000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.